Tumor antigens recognized by T lymphocytes.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Annual Review of Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/annurev.iy.12.040194.002005PMID 8011285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: The pattern of in vitro reactivity predicts the in vivo effect on different tumours

  2005cited by this paper
• Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells

  2005cited by this paper
• Which came first, MHC class I or class II?

  2004cited by this paper
• Three new class I HLA alleles: structure of mRNAs and alternative mechanisms of processing

  2004cited by this paper
• Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes

  2004cited by this paper
• Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.

  1995cited by this paper
• Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.

  1993cited by this paper
• The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas.

  1993cited by this paper
• In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53

  1993cited by this paper
• Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients

  1993cited by this paper
• Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

  1993cited by this paper
• Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.

  1993cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene

  1993cited by this paper
• Properties of a M(r) 110,000 tumor rejection antigen of the chemically induced BALB/c Meth A sarcoma.

  1993cited by this paper
• Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.

  1993cited by this paper
• T cell clones specific for p21 ras‐derived peptides: Characterization of their fine specificity and HLA restriction

  1993cited by this paper
• Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL)

  1993cited by this paper
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993cited by this paper
• Expression of the MuLV‐tumor‐associated antigen is restricted to MuLV‐transformed cells

  1993cited by this paper
• Recognition of shared melanoma antigen by HLA‐A2‐restricted cytolytic T cell clones derived from human tumor‐infiltrating lymphocytes

  1993cited by this paper
• Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein

  1993cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues

  1993cited by this paper
• Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

  1992cited by this paper
• Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

  1992cited by this paper
• Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine

  1992cited by this paper
• Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4− CD8+ cytotoxic T lymphocytes in mice

  1992cited by this paper
• Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia

  1992cited by this paper
• Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

  1992cited by this paper
• In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.

  1992cited by this paper
• MHC class‐I‐restricted auto‐tumor‐specific CD4+CD8 −T‐cell clones established from autologous mixed lymphocyte‐tumor‐cell culture (MLTC)

  1992cited by this paper
• A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability

  1992cited by this paper
• Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

  1992cited by this paper
• Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas.

  1992cited by this paper
• Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

  1992cited by this paper
• Molecular detection and in vivo analysis of the specific T cell response to a protein antigen

  1992cited by this paper
• Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant.

  1992cited by this paper
• Interaction of antigenic peptides with MHC class I molecules on living cells studied by photoaffinity labeling.

  1992cited by this paper
• Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.

  1992cited by this paper
• An analysis of autologous T‐cell anti‐tumour responses in colon‐carcinoma patients following active specific immunization (ASI)

  1992cited by this paper
• T-cell immunity to the joining region of p210BCR-ABL protein.

  1992cited by this paper
• Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

  1992cited by this paper
• Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.

  1992cited by this paper
• Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide

  1992cited by this paper
• Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells

  1992cited by this paper
• Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

  1992cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

  1992cited by this paper
• Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.

  1992cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.

  1991cited by this paper
• Efficiency of peptides and lipopeptides for in vivo priming of virus‐specific cytotoxic T cells

  1991cited by this paper
• Loss of HLA heavy chain and beta 2-microglobulin in HLA negative tumours.

  1991cited by this paper
• Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

  1991cited by this paper
• Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells.

  1991cited by this paper
• T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.

  1991cited by this paper
• Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction

  1991cited by this paper
• Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins

  1991cited by this paper
• Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor.

  1991cited by this paper
• Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggests an allele-specific T cell epitope forecast

  1991cited by this paper
• Efficacy studies on a canarypox-rabies recombinant virus.

  1991cited by this paper
• The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

  1991cited by this paper
• New use of BCG for recombinant vaccines

  1991cited by this paper
• Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

  1991cited by this paper
• Cellular peptide composition governed by major histocompatibility complex class I molecules

  1990cited by this paper
• Generation of a cytotoxic T‐lymphocyte response using a Salmonella antigen‐delivery system

  1990cited by this paper
• Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.

  1990cited by this paper
• Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells

  1990cited by this paper
• Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.

  1990cited by this paper
• Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide

  1990cited by this paper
• In search of the 'missing self': MHC molecules and NK cell recognition.

  1990cited by this paper
• Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells

  1990cited by this paper
• Presentation of viral antigen controlled by a gene in the major histocompatibility complex

  1990cited by this paper
• Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.

  1990cited by this paper
• Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule

  1990cited by this paper
• Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins.

  1990cited by this paper
• Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit.

  1990cited by this paper
• Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

  1990cited by this paper
• Antigens recognized on a melanoma cell line by autologous cytolytic T lymphocytes are also expressed on freshly collected tumor cells

  1990cited by this paper
• Structure of the gene of tum‐ transplantation antigen P35B: presence of a point mutation in the antigenic allele.

  1990cited by this paper
• The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

  1989cited by this paper
• Presence on a human melanoma of multiple antigens recognized by autologous CTL

  1989cited by this paper
• Murine 86- and 84-kDa heat shock proteins, cDNA sequences, chromosome assignments, and evolutionary origins.

  1989cited by this paper
• Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

  1989cited by this paper
• FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens

  1989cited by this paper
• Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA

  1989cited by this paper
• Selective loss of beta 2-microglobulin mRNA in human colon carcinoma

  1989cited by this paper
• Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

  1989cited by this paper
• Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.

  1989cited by this paper
• Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma.

  1989cited by this paper
• Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens

  1989cited by this paper
• Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

  1989cited by this paper
• HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas.

  1989cited by this paper
• Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

  1989cited by this paper
• Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells

  1989cited by this paper

• Epithelial-mesenchymal transition in cancer: A focus on itraconazole, a hedgehog inhibitor.

  2025cites this paper
• IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells

  2025cites this paper
• The potential of chimeric antigen receptor -T cell therapy for endocrine cancer

  2025cites this paper
• PHbinder and PSGM: A Cascaded Framework for Epitope Prediction and HLA-I Allele Identification

  2025cites this paper
• The regulatory role and mechanism of energy metabolism and immune response in head and neck cancer

  2025cites this paper
• Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies

  2025cites this paper
• A Challenging Case of Immune-Related Organizing Pneumonitis Following Programmed Cell Death 1 Inhibitor Therapy in Non-Small Cell Lung Cancer

  2025cites this paper
• Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL

  2025cites this paper
• Bifurcation and chaos in tumor-immune dynamics with IL-2: A comparative study of continuous and discrete-time models

  2025cites this paper
• Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy.

  2025cites this paper
• Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy

  2025cites this paper
• War or peace: Viruses and metastasis.

  2024cites this paper
• SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity

  2024cites this paper
• FloraStilbene: immunotherapy adjuvant for breast cancer

  2024cites this paper
• Public neoantigens in breast cancer immunotherapy (Review)

  2024cites this paper
• An Insight into Immunological Therapeutic Approach against Cancer: Potential Anti-cancer Vaccines

  2024cites this paper
• Cancer Vaccines: Another Aspect to Immunotherapy

  2024cites this paper
• Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.

  2024cites this paper
• Anticancer immune reaction and lymph node sinus macrophages: a review from human and animal studies

  2024cites this paper
• A Plausible Framework Reveals Potential Similarities in the Regulation of Immunity against Some Cancers and Some Infectious Agents: Implications for Prevention and Treatment

  2024cites this paper
• Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies

  2024cites this paper
• Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip

  2024cites this paper
• Phosphatidylserine externalization as immune checkpoint in cancer

  2024cites this paper
• Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA

  2023cites this paper
• Heterogeneity of tertiary lymphoid structures in cancer

  2023cites this paper
• From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers.

  2023cites this paper
• Molecular approaches to identify cancer T cell antigens and improve immunogenicity

  2023cites this paper
• Leveraging mesoporous silica nanomaterial for optimal immunotherapeutics against cancer

  2023cites this paper
• Molecular approaches to identify cancer T cell antigens and improve immunogenicity

  2023cites this paper
• Células T modificadas con receptores quiméricos de antígeno: ingeniería genética y aplicaciones clínicas en cáncer pediátrico. Revisión de la literatura

  2023cites this paper
• Cancer Immunotherapy: Where Next?

  2023cites this paper
• Integrating immunopeptidome analysis for the design and development of cancer vaccines.

  2023cites this paper
• Distinct mutational processes shape selection of MHC class I and class II mutations across primary and metastatic tumors

  2023influential citation
• HLAProphet: Personalized allele-level quantification of the HLA proteins

  2023cites this paper
• Peptide-Based Therapeutics in Cancer Therapy

  2023cites this paper
• Molecular approaches to identify cancer T cell antigens and improve immunogenicity

  2023cites this paper
• Molecular approaches to identify cancer T cell antigens and improve immunogenicity

  2023cites this paper
• Group 2 innate lymphoid cells boost CD8+ T-cell activation in anti-tumor immune responses

  2023cites this paper
• Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA.

  2022cites this paper
• Peptides for Vaccine Development

  2022cites this paper
• A Commotion in the Skin: Developing Melanoma Immunotherapies.

  2022cites this paper
• Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?

  2022cites this paper
• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

  2022cites this paper
• Keep a Little Fire Burning—The Delicate Balance of Targeting Sphingosine-1-Phosphate in Cancer Immunity

  2022cites this paper
• Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers

  2022influential citation
• Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma

  2022cites this paper
• Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling.

  2022cites this paper
• Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

  2022cites this paper
• Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms

  2022cites this paper
• Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer

  2022cites this paper
• Somatic cancers: Hijacking germ cell immortality tools

  2022cites this paper
• Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization

  2021cites this paper
• Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer

  2021cites this paper
• Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms

  2021cites this paper
• Identification of immune‐related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma

  2021cites this paper
• Influence of Immune Microenvironment on Diagnosis and Prognosis of Head and Neck Squamous Cell Carcinoma

  2021cites this paper
• FOXP3+ regulatory T cells and age‐related diseases

  2021cites this paper
• A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9

  2021cites this paper
• Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors

  2021cites this paper
• Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential

  2021cites this paper
• Anti-cancer Immune Reaction and Lymph Node Macrophage; A Review from Human and Animal Studies

  2021cites this paper
• T Cells Expanded from PD-1+ Peripheral Blood Lymphocytes Share More Clones with Paired Tumor-Infiltrating Lymphocytes

  2021cites this paper
• Tumor Immunology: Understanding the Immune System and Cancer to Enhance the Efficacy of Cancer Immunotherapies

  2021cites this paper
• Prognostic value of the density of tumor-infiltrating lymphocytes in colorectal cancer liver metastases

  2021cites this paper
• Trials of Immunotherapy in Triple Negative Breast Cancer

  2021cites this paper
• The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell Therapy

  2021cites this paper
• Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic T‐cells and tumour cells

  2021cites this paper
• TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes

  2021cites this paper
• Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes

  2021cites this paper
• TAP 1.0: A robust immunoinformatic tool for the prediction of tumor T-cell antigens based on AAindex properties

  2021cites this paper
• C‐C chemokine hepatocellular carcinoma motif ligand 5‐deficiency promotes hepatocellular carcinoma progression by affecting B cell recruitment

  2021cites this paper
• Antigenic Essence: Upgrade of Cellular Cancer Vaccines

  2021cites this paper
• Understanding relevant immune mechanisms in gastrointestinal oncology

  2021cites this paper
• The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy

  2021cites this paper
• Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

  2021cites this paper
• Functional T Cell Reactivity to Melanocyte Antigens is Lost During Development of Malignant Melanoma, but is Restored with Successful Immunotherapy

  2020cites this paper
• [Management of immune checkpoint inhibitors-induced liver toxicity in cancer].

  2020cites this paper
• Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy

  2020cites this paper
• Dynamics analysis in a tumor-immune system with chemotherapy

  2020cites this paper
• Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

  2020cites this paper
• Immunotherapy for Localized Prostate Cancer: The Next Frontier?

  2020cites this paper
• Thrombozytäre PD-L1 Expression als Biomarker in Patienten mit nicht-kleinzelligem Bronchialkarzinom

  2020cites this paper
• Management of Immune Checkpoint Inhibitor Toxicities

  2020cites this paper
• Germline Genetic Determination of Cancer Outcome

  2020cites this paper
• New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.

  2020cites this paper
• Novel antibody-based therapeutic approaches for redirecting T cell effector functions towards tumors expressing CD248 (TEM1)

  2020cites this paper
• Immunohistochemical expression of β-catenin, Ki67, CD3 and CD18 in canine colorectal adenomas and adenocarcinomas

  2020cites this paper
• A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees

  2020cites this paper
• Immunotherapy and Radiation.

  2020cites this paper
• Immunotherapy Models

  2020cites this paper
• Management of Immune Checkpoint Inhibitor Toxicities

  2020cites this paper
• Immune crosstalk in cancer progression and metastatic spread: a complex conversation

  2020cites this paper
• Clinical and molecular insights into BCG immunotherapy for melanoma

  2020cites this paper
• Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells

  2020cites this paper
• The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score

  2019cites this paper
• Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response against the AH1 tumor rejection antigen

  2019cites this paper
• Immunotherapy in Oncology

  2019cites this paper
• Nanodrug delivery systems in cancer

  2019cites this paper
• CD4+ versus CD8+ T-lymphocyte identification in an integrated microfluidic chip using light scattering and machine learning.

  2019cites this paper
• Current Perspectives on Nasopharyngeal Carcinoma.

  2019cites this paper